Related Experiment Video
Updated: Jul 18, 2026

Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats
Published on: March 11, 2016
Serial echocardiographic changes in patients on hemodialysis: an evaluation of guideline implementation
Adrian Covic1, Nicoleta G I Mardare, Serban Ardeleanu
1Dialysis and Transplantation Center, 'Dr. C.I. Parhon' University Hospital, Iasi, Romania. acovic@xnet.ro
Insights
This study shows that guideline-based interventions can reduce left ventricular mass (LVM) and improve heart function in hemodialysis patients. Key factors for regression include managing anemia and mineral metabolism.
Area of Science:
- Cardiology
- Nephrology
- Medical Diagnostics
Background:
- Limited research exists on serial changes in left ventricular mass (LVM) and associated risk factors, especially post-guideline implementation.
- Previous studies predated current evidence-based practice guidelines (EBPG) and Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines.
Purpose of the Study:
- To prospectively track left ventricular (LV) structure and function.
- To identify risk factors for LVM progression using serial echocardiography.
- To assess trends after implementing EBPG.
Main Methods:
- 103 hemodialysis patients (mean age 51) with a minimum 12-month follow-up were analyzed.
- Echocardiography, blood pressure, and biochemical data were collected at baseline and end-of-study.
- Monthly averages of biochemical and BP data were used for analysis.
Main Results:
- Baseline prevalence of left ventricular hypertrophy (LVH) was 86.4%; systolic dysfunction was 25.6%.
- LVMI correlated with hemoglobin, serum phosphate, calcium x phosphate product, and cholesterol.
- Independent predictors for LVMI were anemia and mineral metabolism markers.
- 62.1% of patients showed LVMI regression (mean decrease 12 g/m²).
- Regression was associated with improved anemia, serum phosphate, and calcium x phosphate product.
Conclusions:
- A comprehensive, guideline-driven approach can partially reverse LV structural and functional abnormalities in hemodialysis patients.
- Targeting pathogenic mechanisms like anemia and mineral metabolism is crucial for improving cardiac outcomes.
Background:
Few studies have addressed the description of serial changes in left ventricular mass (LVM) and relevant risk factors. All these studies were initiated before the implementation of EBPG or K/DOQI guidelines. The aims of our study were to prospectively describe trends in left ventricular (LV) structure and function, evaluate risk factors for progression of LVM derived from serial echocardiographic measurements starting January 2003, 6 months after full implementation of EBPG in our unit.
Methods:
One hundred seventy-six patients were enrolled at baseline, between 1 January 2003 and 1 October 2004; 33 patients were excluded from analysis due to poor echocardiographic window, 14 patients died and 26 were transplanted or transferred during the follow-up period of minimum 12 months. One hundred and three patients were included in the final analysis (mean age 51 years, mean follow-up 24.1 +/- 14.4 months). Echocardiography was performed at inclusion and at the end of study. Biochemical, blood pressure (BP) and medication data were collected and the means of monthly values were used.
Results:
At baseline, 86.4% of the patients had left ventricular hypertrophy (LVH) (56.3% concentric hypertrophy, 30.1% eccentric hypertrophy, 6.8% concentric remodeling and only 6.8% normal LV geometry), 25.6% had systolic dy-sfunction and 50.5% had abnormal LV volume index (LVVI). Similar data were recorded at follow-up (82.5%, 44.7%, 37.9%, 7.7%, 9.7%, and 19.5%, respectively). Baseline left ventricular mass index (LVMI) significantly correlated with hemoglobin (Hb) and total protein level. LVMI at follow-up correlated to Hb, SBP, PP, mean level of serum phosphate, calcium x phosphate product and cholesterol. Independent predictors for LVMI (multiple regressions) were anemia and mineral metabolism markers. In our population, 62.1% of the patients had a regression of LVMI, with a mean decrease in LVMI of 12 g/m 2 (1.7 +/- 11.7 g/m 2 /month) over more than 12 months of guideline implementation. Regressors had a significant improvement of anemia, serum phosphate level and calcium x phosphate product (p<0.05).
Conclusion:
Our study suggests that a holistic interventional approach, targeting various pathogenic mechanisms, as per guidelines, can elicit at least a partial regression in LV structural and functional abnormalities in hemodialysis patients.
Related Concept Videos
Imaging Studies for Cardiovascular System I:Echocardiography
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion, evaluates...
Hemodialysis II: Procedure and Complications
Hemodialysis III: Nursing Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Chronic Kidney Disease IV: Nursing Management
Hemodialysis I: Introduction